Drug Profile
Verekitug - Upstream Biosciences
Alternative Names: ASP-7266; UPB-101Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Upstream Biosciences
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action CRLF2-protein-antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Nasal polyps; Rhinosinusitis